147 related articles for article (PubMed ID: 34488125)
1. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
4. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Karakas D; Ozpolat B
J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
[TBL] [Abstract][Full Text] [Related]
5. Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.
Comert Onder F; Siyah P; Durdagi S; Ay M; Ozpolat B
RSC Med Chem; 2022 Jul; 13(7):840-849. PubMed ID: 35923718
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Liu R; Proud CG
Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
[TBL] [Abstract][Full Text] [Related]
8. In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors.
Liu Z; Jiang A; Wang Y; Xu P; Zhang Q; Wang Y; He S; Wang N; Jin H; Zhang B
Bioorg Med Chem Lett; 2022 Jul; 67():128759. PubMed ID: 35483594
[TBL] [Abstract][Full Text] [Related]
9. Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.
Fu Q; Liu X; Li Y; Wang P; Wu T; Xiao H; Zhao Y; Liao Q; Song Z
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956836
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Ju Y; Ben-David Y; Rotin D; Zacksenhaus E
Sci Rep; 2021 Apr; 11(1):9181. PubMed ID: 33911160
[TBL] [Abstract][Full Text] [Related]
12. Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.
Yao Z; Li J; Liu Z; Zheng L; Fan N; Zhang Y; Jia N; Lv J; Liu N; Zhu X; Du J; Lv C; Xie F; Liu Y; Wang X; Fei Z; Gao C
Mol Biosyst; 2016 Mar; 12(3):729-36. PubMed ID: 26776155
[TBL] [Abstract][Full Text] [Related]
13. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
Comert Onder F; Durdagi S; Sahin K; Ozpolat B; Ay M
J Chem Inf Model; 2020 Mar; 60(3):1766-1778. PubMed ID: 32027127
[TBL] [Abstract][Full Text] [Related]
16. Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.
Wang X; Xie J; da Mota SR; Moore CE; Proud CG
Biochem J; 2015 Apr; 467(2):321-31. PubMed ID: 25670349
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
Xie J; Shen K; Lenchine RV; Gethings LA; Trim PJ; Snel MF; Zhou Y; Kenney JW; Kamei M; Kochetkova M; Wang X; Proud CG
Int J Cancer; 2018 May; 142(9):1865-1877. PubMed ID: 29235102
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
Fu LL; Xie T; Zhang SY; Liu B
Apoptosis; 2014 Oct; 19(10):1527-31. PubMed ID: 25023961
[TBL] [Abstract][Full Text] [Related]
19. [Eukaryotic elongation factor 2 kinase and cancer].
Wang GZ; Qi X; Li J
Yao Xue Xue Bao; 2015 Jul; 50(7):808-13. PubMed ID: 26552140
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
Zhu H; Yang X; Liu J; Zhou L; Zhang C; Xu L; Qin Q; Zhan L; Lu J; Cheng H; Sun X
Cell Stress Chaperones; 2015 Mar; 20(2):217-20. PubMed ID: 25248493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
